Background: With the introduction of the anti-CD20 antibody rituximab, the outcome of patients with follicular lymphoma (FL) has greatly improved over the last two decades. First-line prolonged rituximab monotherapy is effective, achieving longterm remission and prolonged failure-free survival in some patients. Additionally, rituximab has been shown to synergize with chemotherapeutic and novel targeted agents alike with measurable gains in duration of response. As such, rituximab has made its mark in the treatment of FL and remains a valid agent despite the availability of newer monoclonal antibodies. This review summarizes the evolving role of rituximab as the first available anti-CD20 monoclonal antibody, emphasizing its clear activity as a single agent and in combination with chemotherapy or molecular targeted agents, and setting the standard for the development of new anti-CD20 monoclonal antibodies.
Introduction
Follicular lymphomas (FL), the most common indolent subtype, is genetically characterized by the chromosomal translocation t(14; 18)(q32; q21), which results in constitutive overexpression of the BCL2 gene, allowing B cells to abrogate the default germinal center apoptotic program [1] . The outcome of patients with FL has continuously and significantly improved during the last two decades [2] [3] [4] [5] [6] , mainly due to the use of the anti-CD20 antibody rituximab, with an expected median survival approaching or even exceeding 20 years, particularly in younger patients [2, 4, 7] .
FL is a chemotherapy sensitive disease with subsets of patients deriving durable remissions with available treatments. The Follicular Lymphoma International Prognostic Index (FLIPI) [8] has become the most widely used prognostic tool for overall survival. However, the FLIPI was introduced in the pre-rituximab era and has not been validated as a predictive tool for treatment selection. A new prognostic index (FLIPI-2) for progression-free survival (PFS), based on prospectively collected data in patients treated with rituximab-containing regimens, has subsequently been developed [9] , and may allow better patient stratification for clinical trials, though not extensively used [10] .
Such prognostic indices are limited in their ability to capture the clinical heterogeneity of the disease. Some patients remain alive for decades without need for treatment, while others have aggressive disease with transient responses to treatment and/or histologic transformation to higher-grade lymphomas [11] [12] [13] . Hence, in spite of the FLIPI and FLIPI-2, the decision to treat FL patients remains largely influenced by the extent of tumor burden and the presence of symptoms [10] .
During the last two decades, treatment strategies have changed due to the continuous development and introduction of novel immunotherapy-containing therapeutic approaches [14] [15] [16] [17] . Several targeted drugs have also shown clinical efficacy and a favorable safety profile in early clinical trials, holding promise of an upcoming time of safe and effective chemotherapy-free strategies. Most responses however, are partial and may require extended treatment duration, mostly until disease progression. Additionally, recent trials of combinations of new agents have been terminated because of life-threatening complications and treatment-related deaths [18] [19] [20] . How to better combine these new agents with each other and with immuno-chemotherapy is becoming increasingly crucial. This Review serves to summarize the evolving role of rituximab, an anti-CD20 antibody, as the first available targeted drug, and address its role as monotherapy and in combinatorial chemotherapy-free strategies for the treatment of FL.
Rituximab monotherapy in FL
For asymptomatic patients with advanced-stage and low tumor burden, randomized studies have confirmed that systemic treatment can be deferred until the development of symptoms or organ failure without impairing overall survival; as such, a watchful waiting policy has long remained a widely accepted approach [21] . This approach was recently challenged by a randomized study showing that rituximab monotherapy may be used in such patients, and when administered with a maintenance schedule, could be delivered with minimal toxicity and resultant improvements in quality of life compared with watchful waiting, but without any survival benefit [22] . Another large randomized study, however, indicated that maintenance rituximab may not be needed in the setting of newly diagnosed FL patients with low tumor burden responding to single-agent rituximab induction, establishing equivalent outcomes with a rituximab re-treatment strategy [23] .
For symptomatic patients in need of therapy, rituximabthough more extensively studied in combination with chemotherapy-was shown to have relevant single agent activity, with response rates of 50%-70% and event-free survival (EFS) of 1-3 years, depending on the population studied [24] [25] [26] [27] [28] [29] [30] . In fact, rituximab was first approved as a single agent in the relapsed/ refractory indolent non-Hodgkin Lymphoma population based on a pivotal trial that enrolled 166 heavily pretreated patients and demonstrated a 48% response rate achievable with Rituximab 375 mg/m 2 weekly for four doses [25] . Following this, clinical studies developed and conducted by the Swiss Group for Clinical Cancer Research (SAKK) and the Nordic Lymphoma Group (NLG) were among the first to focus on the role of rituximab monotherapy in the initial treatment of FL [26] [27] [28] [29] [30] , and demonstrated that a sizeable portion of FL patients might not need front-line chemotherapy [26] [27] [28] [29] [30] .
The SAKK 35/98 trial investigated the potential benefits of extended rituximab treatment comparing a standard schedule of rituximab induction (375 mg/m 2 weekly four times) with a prolonged treatment schedule (standard induction plus 375 mg/m 2 every 2 months for four times for a total of eight rituximab infusions). In 185 evaluable patients with newly diagnosed or refractory/relapsed FL, the overall remission rate (ORR) after rituximab induction was 67% in chemotherapy-naïve patients and 46% in pretreated cases (P < 0.01). Patients responding or with stable disease (N ¼ 151) were randomized to observation with no further treatment or prolonged rituximab administration. At a median follow-up of 35 months, the median EFS was 1 year in the observation arm versus 2 years in the prolonged treatment arm (P ¼ 0.02). The difference was particularly notable in chemotherapy-naïve patients (19 versus 36 months; P ¼ 0.009) and in patients responding to induction treatment (16 versus 36 months; P ¼ 0.004) [26] . A subsequent long-term analysis of this trial at a median follow-up of 9 years showed that the EFS plateaued for untreated patients responding to rituximab induction enrolled in the prolonged treatment arm with a rate of 45% at 5 and 8 years [27] . The only favorable prognostic factor for EFS using these long-term followup data in a multivariate Cox regression was the prolonged rituximab schedule (HR 0.59; 95% CI 0.39-0.88; P ¼ 0.009). Of interest, 85% of patients in this study had advanced stage and more than half had bulky lesions, suggesting efficacy of rituximab even in subsets of patient with high tumor burden.
The following trial, SAKK 35/03, evaluated the safety and efficacy of rituximab maintenance for up to 5 years after induction with 4 weekly doses of rituximab, in 270 patients with FL. 165 patients were randomized, 82 in arm A (rituximab 375 mg/m 2 every 2 months four times) and 83 in arm B (rituximab 375 mg/ m 2 every 2 months for 5 years or until PD, relapse or unacceptable toxicity). A total of 124 patients were chemotherapy-naïve. Median EFS was 3.4 years (95% CI 2.1-5.3) in arm A and 5.3 years (95% CI 3.5-NA) in arm B. PFS was also longer in the prolonged treatment arm but OS and observed best remission were not significantly different with concerns raised for increased toxicity with longer maintenance [28] .
These studies and those of others [31, 32] did not entirely clarify the optimal duration of rituximab administration, but the prolonged regimen of one infusion of rituximab per week for 4 weeks followed by a consolidation dose every 2 months for 8 months became an accepted front-line approach for FL in most Swiss onco-hematology institutions [11] .
Another modality for the administration of immunotherapy without chemotherapy as the initial treatment of FL was investigated in a phase II randomized trial of the NLG [29] . This randomized phase II trial evaluated the effect and safety of interferon-alpha2a (IFN) in combination with extended rituximab, in patients with symptomatic, advanced indolent lymphoma responding to a standard 4-weekly course of rituximab. IFN was added to the experimental arm with the intent of improving rituximab efficacy, through its immune stimulating effects on natural killer cells and monocytes to enhance antibodydependent cellular cytotoxicity (ADCC). A total of 123 patients were treated with rituximab 375 mg/m 2 once weekly Â4 infusions. Complete response was achieved by 11% of patients; partial and minor responses were seen in 46% and 11%, respectively. Patients with either partial or minor response after four rituximab doses were randomized to four more infusions of rituximab alone or in combination with 5 weeks of IFN (N ¼ 33), with an overall response rate of 78% and 94%, respectively. The combination with IFN improved long-term molecular complete remissions (CRs) and prolonged failure-free survival without chemotherapy [29] . In a subsequent phase III study by the NLG [30] , patients with advanced CD20þ indolent lymphoma, in need of therapy, were randomized to rituximab (4 weekly infusions of 375 mg/m 2 ) or to rituximab combined with 5 weeks of IFN-a2a (3-4.5 MIU daily) as priming. Responding patients were eligible for a second cycle with the same allocated to treatment. Although CRs were higher in the combination arm, with long median follow-up of 61 months, 33% were still failure-free with an OS rate of 88% with no difference between treatment groups. Given similar overall survival achievable with rituximab monotherapy and considerable toxicity with IFN, IFN has fallen out of favor in hematologic malignancies. Nonetheless, results of this trial suggest that chemotherapy can be deferred in a significant proportion of patients without compromising outcomes [30] . Rituximab has since been evaluated in other 'doublet' combinations with novel targeted agents [33, 34] including galiximab, with response improved in those with a low FLIPI [35] , and epratuzumab [36] for treatment naïve FL with response rates and PFS comparable to those observed after standard chemo-immunotherapies (Table 1) .
To improve on the efficacy of rituximab, a new generation of anti-CD20 antibodies including antibody-radioisotope conjugates have been a focus of drug development with variable results. In FL, obinutuzumab, a glyco-engineered type II anti-CD20 monoclonal antibody, appeared superior to rituximab in preclinical studies. However, in a prospective, randomized study comparing safety and efficacy of obinutuzumab with rituximab in relapsed indolent lymphoma, the better overall response rate of obinutuzumab (44.6% versus 33.3%; P ¼ 0.08) did not translate to a PFS or OS improvement [37] . Despite this initial disappointment with obinutuzumab, the GALLIUM and GADOLIN trials have more recently suggested an advantage to utilizing this new antibody with chemotherapy as compared with a rituximab-based regimen, results for which will be discussed in the following sections [38] [39] [40] [41] .
Unlike obinutuzumab, the safety and efficacy of other anti-CD20 antibodies such as veltuzumab, [42] ocrelizumab [43] , and ocaratumumab [44] have not demonstrated a benefit over rituximab while other antibodies such as ublituximab, a unique type I, chimeric, glycol-engineered anti-CD20 mAb, and 90 Y-ibritumomab tiuxetan, comprised of a radiation-emitting radionuclide conjugated to an anti-CD20 monoclonal antibody (radioimmunotherpay/RIT), may have a place in treating rituximabrelapsed/refractory patients with FL [45, 46] . An alternative RIT agent 131 iodine-tositumomab has also been combined with CHOP and shown in a randomized intergroup trial to be comparable to R-CHOP for OS and PFS [47] . The benefit of RIT consolidation after chemo-immunotherapy in the frontline treatment BCL-2, B-cell lymphoma-2; BTK, bruton tyrosine kinase; mPFS, median progression-free survival; PD-1, program death-1; SYK, spleen tyrosine kinase.
of FL remains unclear [16] , and these agents may be inferior to maintenance rituximab [48] . Additionally, given logistical limitations associated with the administration of RIT, use of these agents has not been widely adopted. Nonetheless, taken collectively, it is clear that rituximab has set the standard for continued drug development and treatment strategies in FL and remains an appropriate partner for nonchemotherapy combinatorial strategies.
Rituximab-chemotherapy combinations in high tumor burden FL
For symptomatic patients with high tumor burden in need of treatment, immuno-chemotherapy regimens have clearly improved outcomes compared with chemotherapy alone in FL [49] [50] [51] [52] [53] (Table 2) . ORRs of 81% and CR rates of 41% were reported in treatment-naïve patients with stage III/IV FL treated with R-CVP in a multicenter study [51] , while in a randomized study of second-line treatment in relapsing patients, the R-CHOP regimen achieved ORR and CR rates of 85% and 30%, respectively [15] . Soon after, a randomized study for patients with untreated, advanced-stage FL looked at CHOP alone (N ¼ 205) or R-CHOP (N ¼ 223). R-CHOP reduced the relative risk for treatment failure by 60% and significantly prolonged the time to treatment failure (P < 0.001). Superior OS was demonstrated early on with relatively short follow-up (P ¼ 0.016) [50] . R-CHOP Â6 was then compared with R-CVPÂ8 versus R-FM (fludarabine and mitoxantrone)Â6 in a randomized trial for frontline FL, demonstrating superiority over R-CVP for PFS and less toxicity compared with R-FM [53] . BR, bendamustine-rituximab; BO, bendamustine-obinutuzumab; CR, complete response; mFU, median follow-up; MR, maintenance rituximab; MO, maintenance obinutuzumab; ORR, overall response rates; R-CVP, rituximab-cyclophosphamide, vincristine, prednisone; R-CHOP, rituximab-cyclophosphamide, doxorubicin, vincristine, prednisone; R-FM, rituximab-fludarabine, mitoxantrone; R-FCM, rituximab-fludarabine, cyclophosphamide, mitoxantrone.
More recently, the combination of rituximab and bendamustine (BR) has been compared with R-CHOP/R-CVP in two randomized trials, both demonstrating the non-inferiority of BR [49, 54] . In the BRIGHT study, patients were randomized to BR versus R-CHOP/R-CVP and no patients received maintenance rituximab. BR was shown to be non-inferior to R-CHOP/R-CVP, as assessed by the primary end point of complete response rate (31% versus 25%, respectively; P ¼ 0.0225 for NI [0.88 margin]). The overall response rates for BR and R-CHOP/R-CVP were 97% and 91%, respectively (P ¼ 0.0102) [54] . A second noninferiority randomized trial demonstrated that BR achieved a longer PFS compared with R-CHOP [69.5 months (26.1 to not yet reached) versus 31.2 months (15.2-65.7); hazard ratio 0.58, 95% CI 0.44-0.74; P < 0.0001], with less hematologic toxicity [49] . These trials have established BR as a preferred first-line treatment approach for many although concerns for increased risk of opportunistic infections associated with bendamustine have led to some reservations in firmly adopting this approach in our own practice.
Recently, the phase III GALLIUM study reported results for 1202 patients with previously untreated FL randomized to obinutuzumab versus rituximab with chemotherapy followed by rituximab maintenance [41] . After a median follow-up of 34.5 months, there was a 34% reduction in the risk of progression or death in the obinutuzumab-chemotherapy arm relative to the rituximabchemotherapy arm (HR 0.66; 95% CI 0.51-0.85; P ¼ 0.001). The obinutuzumab-chemotherapy arm induced rapid and more effective tumor cell clearance with increased depth of response in peripheral blood and bone marrow [38] . Similarly, in the GADOLIN trial the obinutuzumab-bendamustine combination was useful in improving overall survival in the rituximab refractory population [39, 40] . This approach, however, is challenged by the increasing use of bendamustine in the front-line setting but does confirm a preserved positive role for anti-CD20 agents in the treatment of FL.
Despite the clinical successes of monoclonal antibodies in combination with bendamustine, there are concerns regarding the potential for increased toxicities associated with both obinutuzumab and bendamustine. The GALLIUM study reported more frequent grade 3-5 adverse events (74.6% versus 67.8%) and serious adverse events (46.1% versus 39.9%) in the obinutuzumab group and rituximab group, respectively. The rates of adverse events resulting in death were similar in the two groups (4.0% versus 3.4% in the obinutuzumab versus rituximab groups). The most common adverse events were infusion-related events and considered to be largely due to obinutuzumab. However, in scrutinizing the data further, it was clear that infections and second neoplasms were higher in patients receiving bendamustine irrespective of the monoclonal antibody used [41] . Similarly, an increased incidence of opportunistic infections and secondary malignancies were noted in the BRIGHT study for patients treated with BR [54, 55] . With these emerging concerns for safety with BR and obinutuzumab-bendamustine, it has been our routine practice to utilize antiviral and antifungal prophylaxis for those patients receiving a bendamustine-based regimen to minimize infection risks.
In high tumor burden FL, several studies have also explored the use of rituximab as maintenance after induction treatment. Treatment with immuno-chemotherapy followed by rituximab maintenance has demonstrated efficacy either as first-line [56, 57] or second-line therapy [15] . The PRIMA study comprehensively evaluated the benefit of maintenance therapy in FL after first induction chemo-immunotherapy. The study enrolled 1217 patients. Most (75%) received R-CHOP induction (22% R-CVP, 3% R-FCM). Patients responding to induction therapy (N ¼ 1018), were stratified based on their immunochemotherapy regimen and response (CR/CRu versus PR) and randomized to observation or rituximab maintenance, one infusion (375 mg/ m 2 ) every 8 weeks for 2 years [57] . With median follow-up of 73 months from randomization, 6-year PFS estimate was 42.7% (95% CI 38% to 46.9%) in the observation arm and 59.2% (95% CI 54.7% to 63.7%) in the rituximab maintenance arm, respectively (stratified Log-Rank, P < 0.0001; HR ¼ 0.58; 95% CI 0.48-0.69) [58] .
However, front-line studies have failed to show an overall survival benefit with maintenance, calling into question the utility for this wide-spread practice [59, 60] . On further analysis, the benefit of maintenance rituximab appears to be dependent on the depth of response achieved with induction and by extension, the type of immuno-chemotherapy induction used [56, 57] . Moreover, the benefit of maintenance after a bendamustineimmunotherapy approach remains unknown. Alternatively, it is clear is that maintenance rituximab increases toxicity without improving quality of life at substantial financial costs [21, 23, 61, 62] . Pertaining to the issue of toxicity, in the PRIMA study, a greater incidence of severe infections was reported in the maintenance arm-grade 2-3 infections occurred in 39% and 24% of patients in the maintenance and observation arms respectively (P < 0.0001). Similarly, in the follow up SAKK 35/03 study, a greater incidence of adverse events of all grades was noted with 5 years versus 8 months of maintenance rituximab (76% versus 50%, P < 0.001) [28] . On the other hand, the RESORT trial reported no difference in illness-related anxiety or quality of life between patients with low tumor burden receiving indefinite therapy versus those treated upon progression [23] . As such, rituximab maintenance continues to remain a controversial practice.
Collectively, incremental effects on clinical outcomes with the outlined changes in practice for the treatment of FL have helped to improve the survival of FL patients [4, 7, 63] . As such, the long-term safety of treatments and late effects are becoming important considerations. For these reasons, in spite of the excellent activity of 'standard' immuno-chemotherapy strategies, the availability of several active targeted agents has generated a renewed interest in developing a chemotherapy-free therapeutic approach, with the goal of limiting or delaying non-specific cytotoxic exposure. Of these alternative strategies, targeted agents as adjuncts to an immunotherapy backbone, justified by rituximab's established efficacy as monotherapy in the FL population, are showing great promise.
Novel chemotherapy-free combinations utilizing rituximab
The presented data suggest that anti-CD20 antibodies should be considered a benchmark in the development of chemotherapyfree treatment strategies for FL. Clearly, anti-CD20 antibodies continue to have a role as the sole initial treatment of symptomatic patients with low-grade FL and potentially even in subsets with high tumor burden [26, 27] . As such, these agents remain sound comparators and/or adjuncts to investigate chemotherapy-free alternatives moving forward.
For a chemotherapy-free strategy, clinical studies of rituximab or obinutuzumab combinations with other immunotherapies and/or targeted agents are underway (Table 1) [33] [34] [35] [36] [64] [65] [66] , rationalized by the recognition that the FL micro-environment [67] and its interaction with BCR signaling [68] , contribute to the pathogenesis of the tumor. As such, immunomodulatory agents, BCR signaling antagonists, antiapoptotic agents and histone deacetylase inhibitors are among the pipeline of drugs being studied in combination with rituximab/anti-CD20 monoclonal antibodies.
Promising results have been reported with the combination of rituximab and lenalidomide. Indeed, lenalidomide enhances natural killer cell and monocyte-mediated ADCC, thereby enhancing the activity of rituximab against CD20þ tumor cells in vitro and in animal models [69, 70] . This expected synergism was confirmed in early clinical experiences. In recurrent FL, the Cancer and Leukemia Group B (Alliance) 50401 randomized phase II trial evaluated rituximab weekly for 4 weeks, lenalidomide (15 mg/day on days 1-21 of a 28 day cycle in cycle 1 and then 20 mg/day on days 1-21 of a 28-day cycle, in cycles 2-12), or lenalidomide with rituximab (R 2 ) The rituximab-alone arm was discontinued as a result of poor accrual. R 2 was found to be more active with higher response rates and durability of response than lenalidomide alone with similar toxicity [71] .
In a phase II study for advanced stage untreated indolent lymphoma, at the MD Anderson Cancer Center, R 2 , lenalidomide (20 mg/day on days 1-21 of each 28-day cycle), and rituximab (375 mg/m 2 on day 1 of each cycle), were given for up to 12 cycles in responding patients. Out of 46 assessable patients with FL, 40 (87%) had a CR/unconfirmed CR (Cru) and five (11%) had a partial response [72] . With 3 years of follow-up, 79% of FL patients remained in CR. Notably, responses were irrespective of tumor bulk, and GELF criteria, which suggest that chemotherapy-free approaches may be applied to both low tumor and high tumor burden patients. In a similar co-operative group trial, treatment naïve patients with grade 1-3a FL, stage 3-4 or bulky stage 2, FLIPI 0-2 received rituximab 375 mg/m 2 weekly during cycle 1 and day 1 of cycles 4, 6, 8, and 10, plus lenalidomide 20-25 mg on days 1-21 for twelve 28-day cycles. The most prominent grade !3 toxicity was hematologic and most common grade 1-2 toxicities included fatigue (78%), diarrhea (37%), rash (32%). Despite these toxicities, 51 of the 66 patients completed all 12 cycles with 2-and 5-year PFS rates of 86% and 70%, respectively, and a 5-year OS rate of 100% [66] .
The SAKK 35/10 phase II study was developed and conducted by the SAKK in cooperation with the NLG to compare the activity of R 2 versus single-agent rituximab in first-line therapy for FL [73] . The preliminary results showed that patients treated with R 2 in comparison with those receiving rituximab monotherapy had a significantly higher CR/CRu rate in the intention-to-treat population by both investigator assessment (CR/CRu rate, 36% versus 25%, respectively) [73] and independent response review of CT scans (CR/CRu rate, 61% versus 36%) [74] . The response improvement translated into a significant prolonged time to next treatment (P ¼ 0.01) and superior PFS rates (P ¼ 0.03). An improvement in CR30 was also seen in the R 2 arm, 42% (95% CI 30% to 53%) versus 19% (95% CI 11% to 30%) with rituximab alone (P ¼ 0.001). OS rates at 3 years were similar between the arms, 93% (95% CI 85% to 97%) with R 2 versus 92% (95% CI 82% to 96%) with rituximab. An increased but manageable toxicity, mainly hematologic, was seen in the combination arm [73] [74] [75] . An international phase III study (The RELEVANCE Trial, NCT01476787) to compare the combination of rituximab and lenalidomide with rituximab plus chemotherapy in a larger cohort of patients with untreated FL has since completed accrual with results awaited. Positive results for this trial would likely result in a large change in practice patterns with preference for this biologic doublet over standard chemo-immunotherapy options albeit premature without long-term toxicity and outcome data. Alternatively, with negative results, R 2 would still likely maintain a place in the relapsed setting although exploration of biologic mechanisms and predictive biomarkers of response would be of great interest across all patient subsets.
In FL, ibrutinib as a single agent has shown only modest activity in rituximab naïve or sensitive patients in the relapsed/refractory setting [76] . Ibrutinib in combination with rituximab may achieve synergy for greater effect, particularly when used earlier in disease course and in phase II trial for treatment naïve patients, ibrutinib 560 mg once daily until progressive disease or unacceptable toxicity, combined with rituximab 375 mg/m 2 i.v. once weekly for four doses, produced an ORR of 82%, with a CR rate of 27% and a PR rate of 55%, and was well tolerated [77] . Notably, the triplet combination of lenalidomide, ibrutinib, and rituximab has since been investigated and has shown increased toxicity with required dose modifications, and a lack of additional clinical benefit [78] .
With time, it is anticipated that well-tolerated chemotherapyfree approaches will be established and may offer similar durability of responses as to immune-chemotherapy, some also with a potentially finite schedule of administration. However, longterm follow-up will be necessary to confirm clear toxicity profiles and efficacy to justify shifts in treatment strategies.
Discussion Conclusions
To summarize, although no studies have directly compared rituximab alone versus the combination of rituximab plus chemotherapy in untreated FL patients, several groups have shown that first-line prolonged rituximab monotherapy is effective, providing an opportunity to achieve long-term remission and prolonged failure-free survival. This approach may even be effective in subsets of patients with higher burden of disease. Early trials have also demonstrated that the chemotherapy-free combination of interferon with rituximab provides synergistic effects and rationalizes the ongoing exploration of novel biologic doublets. We maintain that anti-CD20 antibodies represent a benchmark in the treatment of FL and remain an appropriate platform upon which to build future clinical trials exploring chemotherapy-free alternatives. Whether a difference in overall survival can ever be captured for a particular novel combination remains questionable given the increasing armamentarium of salvage treatment options, but, it is anticipated that the collective impact of these therapeutic strategies will continue to make measurable gains on survival for FL.
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